Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is rimonabant a safe and effective therapy for sustained weight loss and improved cardiometabolic risk factors?

Nature Clinical Practice Cardiovascular Medicine volume 3, pages 364–365 (2006)Cite this article

An Erratum to this article was published on 01 September 2006

boxed-textPi-Sunyer FX et al. (2006) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295: 761–775

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Douketis JD et al. (2005) Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes (Lond) 29: 1153–1167

    Article  CAS  Google Scholar 

  2. Curioni CC and Lourenco PM (2005) Long-term weight loss after diet and exercise: a systematic review. Int J Obes (Lond) 29: 1168–1174

    Article  CAS  Google Scholar 

  3. Padwal R et al. (2006) Long-term pharmacotherapy for obesity and overweight. The Cochrane Database of Systematic Reviews, Issue 2, Art. No CD004094

    Google Scholar 

  4. James WP et al. (2000) Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 356: 2119–2125

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Claire Braybrook, Assistant Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professor of Nutrition and Head Physician in the Department of Preventive Cardiology, University of Oslo, Oslo, Norway

    Serena Tonstad

Authors
  1. Serena Tonstad
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

S Tonstad has received honoraria from Sanofi-Aventis, the manufacturers of rimonabant for consulting and lectures, as well as Roche and Abbott, the manufacturers of orlistat and sibutramine, respectively.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tonstad, S. Is rimonabant a safe and effective therapy for sustained weight loss and improved cardiometabolic risk factors?. Nat Rev Cardiol 3, 364–365 (2006). https://doi.org/10.1038/ncpcardio0598

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio0598

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing